Werewolf Therapeutics, Inc. (HOWL): Total Liabilities
$44.59M
As of 2025-12-31
$7.86M
As of 2026-06-30
+5.6%
3-year compound annual growth
+44.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.59M | -16.7% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $53.54M | -15.6% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $63.46M | +67.4% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $37.91M | +43.2% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $26.46M | +268.6% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $7.18M | n/a | 2022-03-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | $44.59M | -16.7% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | $8.02M | +180.4% |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | $9.91M | -72.7% |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $27.81M | -17.2% |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | $2.76M | -48.8% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $50.21M | +12.4% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Rallybio Corp (RLYB) | 2025-12-31 | $4.30M | -33.3% |
Compare HOWL, SPRO, CNTX, CRVS side by side · Screen every company in Pharmaceutical Preparations ↗